Page last updated: 2024-11-03

probenecid and Anuria

probenecid has been researched along with Anuria in 2 studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Anuria: Absence of urine formation. It is usually associated with complete bilateral ureteral (URETER) obstruction, complete lower urinary tract obstruction, or unilateral ureteral obstruction when a solitary kidney is present.

Research Excerpts

Excerpt	Relevance	Reference
" Total body clearance (Cltot) and half-life are dependent on renal function as evaluated by estimated creatinine clearance (Clcr)."	2.36	Overview of acyclovir pharmacokinetic disposition in adults and children. ( Blum, MR; de Miranda, P; Liao, SH, 1982)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blum, MR	1
Liao, SH	1
de Miranda, P	1
Kirby, WM	1
Kind, AC	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
An Open Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants[NCT00942084]			Phase 1	32 participants (Actual)	Interventional	2011-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clearance (CL)

"Timeframe:~Version 1:0-5 min,2-4 hrs,6-8 hrs post doses 1 and 5-15; prior to doses 5-15 Version 2:0-15 min post doses 1 and 5-15; within 30 min prior to doses 2 and 5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose" (NCT00942084)
Timeframe: V1:0-5 min,2-4 hrs,6-8 hrs post Doses 1&5-15;prior to doses 5-15; V2:0-15 min post doses 1&5-15; within 30 min prior to doses 2&5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose

Intervention	L/h/kg (Median)
Acyclovir Study Design	0.278

Half-life (T1/2)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	h (Median)
Acyclovir Study Design	7.07

Maximum Steady State Concentration (Cmaxss)

(NCT00942084)
Timeframe: up to 3 dasy of study drug administration and 10 days of safety monitoring

Intervention	mg/L (Median)
Acyclovir Study Design	11.1

Minimum Steady State Concentration (Cminss)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	mg/L (Median)
Acyclovir Study Design	4.15

Steady State Concentration at 50% of the Dosing Interval (C50ss)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	mg/L (Median)
Acyclovir Study Design	6.33

Volume of Distribution (V)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	L/kg (Median)
Acyclovir Study Design	3.34

Reviews

1 review available for probenecid and Anuria

Article	Year
Overview of acyclovir pharmacokinetic disposition in adults and children. The American journal of medicine, 1982, Jul-20, Volume: 73, Issue:1A Topics: Acyclovir; Adult; Aged; Antiviral Agents; Anuria; Blood Proteins; Child; Child, Preschool; Creatinin	1982

Other Studies

1 other study available for probenecid and Anuria

Article	Year
Clinical pharmacology of ampicillin and hetacillin. Annals of the New York Academy of Sciences, 1967, Sep-27, Volume: 145, Issue:2 Topics: Administration, Oral; Ampicillin; Animals; Anuria; Bile; Chemical Phenomena; Chemistry; Humans; Imid	1967